HEALTHMEDPAGE TODAY
FDA Staff Unconvinced Drug for Melanoma Shows Benefit
FDA staff remains unconvinced that the melanoma drug candidate RP1 (vusolimogene oderparepvec) demonstrates sufficient benefit. The drug, previously rejected twice by the FDA, faces potential challenges at an upcoming FDA outside experts meeting.
Related Signal
Adjacent reporting
- FDA Blocked Melanoma Drug as Confusion Reigned Under Makary
- FDA blocked melanoma drug as confusion reigned under Makary
- STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
- STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
- STAT+: FDA to reconsider treatment for rare cancer after surprise rejection
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more